Merck & Co. (MRK) Announces Detailed Results From the Phase 2 CADENCE Study

Merck & Co., Inc. (NYSE:MRK) is one of the best pharma stocks to invest in now. On March 29, Merck & Co., Inc. (NYSE: MRK) announced detailed results from the Phase 2 CADENCE study designed to evaluate the efficacy, safety, and tolerability of two doses of WINREVAIR™ to treat adults with the syndrome of combined post- and precapillary pulmonary hypertension and heart failure with preserved ejection fraction. The company reported that the distinct patient population saw a statistically significant and clinically meaningful reduction from baseline in pulmonary vascular resistance compared to placebo at week 24 with WINREVAIR. It further reported that important secondary endpoints explored included six-minute walk distance, echocardiographic measures, N-terminal pro-B-type natriuretic peptide levels, and time to clinical worsening.

Why Merck & Co (MRK) Continues to Rank Among the Most Profitable Dividend Stocks

Merck & Co., Inc. (NYSE:MRK) stated that the late-breaking data was presented in a late-breaking clinical trial presentation at the American College of Cardiology’s Annual Scientific Session and Expo while simultaneously being published in Circulation and featured as part of an ACC.26 press conference.

Merck & Co., Inc. (NYSE:MRK) is a biopharmaceutical company that delivers health solutions to advance the treatment and prevention of diseases in animals and people. Its Pharmaceutical segment offers vaccines and human health pharmaceutical products, typically therapeutic and preventive agents. Its Animal Health segment develops, discovers, manufactures, and markets a range of vaccines and veterinary pharmaceutical products.

While we acknowledge the risk and potential of MRK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MRK and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.